Biopharmaceutical company HedgePath Pharmaceuticals Inc (OTCQB:HPPI) announced on Monday that it proposes to change its name to INHIBITOR Therapeutics as well as a change its the ticker symbol for common and preferred stock to 'INTI' from 'HPPI'.
Both the corporate name change and ticker symbol change are expected to be effective with the opening of trading on 20 August 2019.
Following the corporate name change, INHIBITOR will launch a new website (http://www.inhibitortx.com) to showcase INHIBITOR's vision and development strategy for SUBA-Itraconazole, a proprietary formulation of the FDA approved anti-fungal drug itraconazole designed to enable improved bioavailability compared to conventional itraconazole when used as an anti-cancer treatment, as well as novel compounds that inhibit upstream targets of the Hedgehog Pathway as treatments for cancer and non-cancerous proliferation disorders.
In addition, SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for INHIBITOR's use in clinical trials. An affiliate of Mayne Pharma is INHIBITOR's majority stockholder and licensor of the SUBA-Itraconazole technology.
Concurrently, INHIBITOR will conduct end of Phase 2 Meeting with FDA in the fourth quarter of 2019 as well as file IND for Phase 2b clinical trial of SUBA-Itraconazole in prostate cancer. It renews and expands exclusive worldwide option agreement with the University of Connecticut for novel compounds that inhibit upstream targets of the Hedgehog Pathway.
Headquartered in Tampa, Florida, INHIBITOR Therapeutics Inc (OTCQB:INTI) is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath is the exclusive US licensee of SUBA-Itraconazole in certain fields.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML